Medication use during the 270 days prior to delivery among 195,272 pregnant women in Alberta, from January 1, 2009, to December 31, 2014.
| Medications | No IA, n = 193,242 | RA, n = 430 | SpA, n = 1600* | p |
|---|---|---|---|---|
| Corticosteroids (prednisone) | 1175 (0.6) | 65 (15.1) | 22 (1.4) | < 0.0001 |
| NSAID | 3023 (1.6) | 49 (11.4) | 41 (2.6) | < 0.0001 |
| First trimester | 2401 (1.2) | 39 (9.1) | 28 (1.8) | |
| Second trimester | 464 (0.2) | 18 (4.2) | 11 (0.7) | |
| Third trimester | 347 (0.2) | 4 (0.9) | 8 (0.5) | |
| Antimalarials | 160 (0.1) | 81 (18.8) | 5 (0.3) | < 0.0001 |
| DMARD** | 42 (0.0) | 34 (7.9) | 6 (0.4) | < 0.0001 |
| Total biologic medications | 114 (0.1) | 36 (8.4) | 27 (1.7) | < 0.0001 |
| Etanercept (TNFi) | 1 (0.0) | 18 (4.2) | 6 (0.4) | |
| Infliximab (TNFi) | 67 (0.0) | 5 (1.2) | 8 (0.5) | |
| Adalimumab (TNFi) | 46 (0.0) | 6 (1.4) | 12 (0.8) | |
| Certolizumab (TNFi) | 0 (0.0) | 3 (0.7) | 0 (0.0) | |
| Golimumab (TNFi) | 0 (0.0) | 1 (0.2) | 1 (0.1) | |
| Abatacept (T cell costimulation inhibitor) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Rituximab (B cell depletory) | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| Tocilizumab (IL-6 receptor blocker) | 0 (0.0) | 3 (0.7) | 0 (0.0) |
All data except p values are n (%).
↵* SpA, ankylosing spondylitis, psoriasis, and psoriatic arthritis. TNFi: tumor necrosis factor inhibitors;
↵** DMARD: disease-modifying antirheumatic drugs including sulfasalazine, cyclosporine, and sodium aurothiomalate; IA: inflammatory arthritis; RA: rheumatoid arthritis; SpA: spondyloarthritis; NSAID: nonsteroidal antiinflammatory drugs; IL: interleukin.